OncoSynergy

About:

OncoSynergy improves outcomes for patients with unmet needs in oncology with resistance mechanism inhibitors.

Top Investors: Connecticut Innovations, NLabs, Korea Information & Communication Co.

Description:

The vision of OncoSynergy, a UCSF spin-out, is to radically improve outcomes for patients with unmet needs in oncology with Resistance Mechanism Inhibitors (RMIs). This new class of therapeutics simultaneously targets multiple hallmarks of cancer progression and have demonstrated dramatic preclinical efficacy as monotherapy and in strategic combinations. It was founded in 2011 and is headquartered in Greenwich, Connecticut.

Total Funding Amount:

$23.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Greenwich, Connecticut, United States

Founded Date:

2011-01-01

Contact Email:

info(AT)oncosynergy.com

Founders:

Anne-Marie Carbonell, Catherine Park, Shawn Carbonell

Number of Employees:

1-10

Last Funding Date:

2020-09-08

IPO Status:

Private

Industries: